How Much Retatrutide Should You Take? A Practical Dosing Guide

Retatrutide at a glance:

• Drug class: Triple agonist (GLP-1, GIP, and glucagon receptors)
• Manufacturer: Eli Lilly
• Route: subcutaneous injection
• Typical frequency: once weekly
• Half-life: approximately 6 days
• Receptor target: GLP-1, GIP, and glucagon receptors

Here's the core rule for Retatrutide dosing: titrate slowly, hold each step long enough, and don't try to outpace your body. Phase 2 trials tested doses up to 12 mg weekly.

Standard Dosing Schedule for Retatrutide

Phase 2 trials tested doses up to 12 mg weekly. As an investigational compound, retatrutide is not commercially available outside clinical trials.

The typical schedule for Retatrutide is once weekly via subcutaneous injection. Half-life of approximately 6 days explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For incretin therapies, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms (nausea, vomiting, diarrhea).

A typical titration plan for Retatrutide holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of Retatrutide is missed: for weekly schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (approximately 6 days) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in Retatrutide side effects and the cost angle of dose escalation in Retatrutide cost.

What the Trials Used

Published trial data for Retatrutide comes primarily from: Jastreboff et al. 2023, NEJM — phase 2 obesity trial showing 24.2% weight loss at 48 weeks at 12 mg.

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For Retatrutide: the standard contraindications for this drug class apply.

Bottom Line

Retatrutide dosing isn't intuitive but it isn't complicated either. Follow the schedule, talk to your prescriber when something feels off, and don't make changes on your own.

Frequently Asked Questions

Related Reading

• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects
• Retatrutide Results: What the Real Numbers Show in 2026
• Retatrutide Cost Explained: Monthly, Yearly, and How to Save
• Retatrutide for Weight Loss: The Complete 2026 Guide
• What Retatrutide Really Looks Like Over 12 Months

Sources

• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.
• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.

This page is informational only and is not medical advice. Always follow your prescribing clinician's dosing instructions.